Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nicotine
Drug ID BADD_D01564
Description Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.
Indications and Usage For the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.
Marketing Status approved
ATC Code N07BA01
DrugBank ID DB00184
KEGG ID D03365
MeSH ID D009538
PubChem ID 89594
TTD Drug ID D0T8GD
NDC Product Code 17205-601; 58316-010; 11673-195; 11673-879; 37808-900; 37808-948; 43598-447; 59450-003; 59779-443; 70000-0115; 0536-1107; 70677-0030; 52922-001; 58316-009; 75877-0002; 11822-3627; 11822-4975; 21130-820; 37808-533; 37808-658; 43598-448; 49035-195; 55910-313; 66715-9802; 66715-9805; 66715-9806; 70000-0114; 28663-009; 58316-006; 11673-727; 11673-881; 37808-682; 0135-0196; 37808-711; 37808-739; 49035-196; 53329-192; 59450-002; 60429-443; 60429-445; 62011-0351; 63868-734; 70677-0032; 60429-444; 0363-0455; 0363-0457; 66715-9804; 68016-288; 28663-010; 58316-011; 11822-4973; 37808-753; 43598-446; 0009-5401; 50090-1148; 53329-193; 68016-289; 0536-1108; 58316-008; 29485-5271; 50090-2860; 63981-124; 66715-9803; 68196-194; 0536-1106; 61252-3005; 50090-1697; 59450-001; 63981-190; 70677-0031; 0135-0194; 0135-0195; 49035-782; 49348-788; 50090-2837; 59779-445; 62011-0350; 63868-735; 66715-9801; 68016-290; 69842-828; 50392-101; 55742-003; 11673-971; 11822-4974; 37808-707; 37808-849; 50090-6383; 55741-449; 59779-448; 0363-0451; 62011-0349; 81870-001; 11673-269; 11673-424; 21130-269; 43598-445; 53329-191; 69842-605; 70000-0113; 58316-007; 11673-194; 11673-196; 29485-5270; 37808-383; 37808-911; 49035-194; 0009-5400
UNII 6M3C89ZY6R
Synonyms Nicotine | Nicotine Bitartrate | Nicotine Tartrate
Chemical Information
Molecular Formula C10H14N2
CAS Registry Number 54-11-5; 22083-74-5
SMILES CN1CCCC1C2=CN=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001---
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abnormal dreams17.15.02.001; 19.02.03.0010.002194%-
Abnormal faeces07.01.03.001---
Abortion spontaneous18.01.04.0010.001881%-
Acne23.02.01.001---
Acute respiratory distress syndrome10.02.01.067; 22.01.03.001; 24.03.02.0340.000627%
Ageusia07.14.03.003; 17.02.07.0010.002131%-
Aggression19.05.01.0010.000940%-
Agitation17.02.05.012; 19.06.02.001--
Agitation neonatal17.02.05.028; 18.04.04.0020.000627%-
Amnesia17.03.02.001; 19.20.01.001--
Anaphylactic reaction10.01.07.001; 24.06.03.0060.003260%
Anaphylactic shock10.01.07.002; 24.06.02.0040.000940%-
Aneurysm24.02.01.001---
Anger19.04.02.0010.000940%-
Angina pectoris02.02.02.002; 24.04.04.0020.001254%
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.0010.002507%-
Anxiety19.06.02.0020.012035%
Apathy19.04.04.002---
Aphasia17.02.03.001; 19.21.01.001--
Aphonia17.02.08.009; 19.19.01.002; 22.12.03.0010.001379%
Aphthous ulcer07.05.06.002---
Application site dermatitis08.02.01.018; 12.07.01.018; 23.03.04.014---
Application site erythema08.02.01.001; 12.07.01.001; 23.03.06.0050.016925%-
Application site irritation08.02.01.003; 12.07.01.0030.010218%-
Application site oedema08.02.01.020; 12.07.01.020---
Application site pain08.02.01.004; 12.07.01.0040.003072%-
Application site pruritus08.02.01.005; 12.07.01.005; 23.03.12.0040.017990%-
The 1th Page    1 2 3 4 5    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene